AUPHAurinia Pharmaceuticals
+1.0% today · +13.8% over a year
No score: too little data.
Quality: among the best of its peers. No dividend.
Aurinia Pharmaceuticals (AUPH) belongs to the Health care sector and is listed on Nasdaq; country: Canada. Its market value is about €2B. Over the past 12 months the price changed by +13.8%, with an annualised volatility of 36% and a largest fall of 22%.
Smart Score
How it is scored →Not scored: not enough data for a fair comparison.
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Gross profit growth / assets (5 y)supports the score · better than 88% of peers
- Accrualsweighs on the score · better than 1% of peers
- Return on equitysupports the score · better than 98% of peers
Red flags and notes
- Caution. Accruals or the Beneish M-score are in the watch zone. More in the glossary → Accruals or the Beneish M-score are in the watch zone.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/E
- 7.1
- P/B
- 3.4
- P/S
- 6.9
- Market cap (EUR)
- €2B
Profitability and debt
- Return on equity
- 61.4%
- Gross margin
- 90.6%
Dividends
- Dividend yield
- 0.00%
- Years without a lower dividend
- 0
Returns and risk
- 1 day
- +1.0%
- 1 month
- −0.2%
- 1 year
- +13.8%
- Volatility, 1 yr
- 35.8%
- Max drawdown, 1 yr
- −21.8%
- Beta
- 0.54
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| PHVSPharvaris N.V. | 2/10 | 0.0% | 59.7% |
|---|---|---|---|
| NAMSNewAmsterdam Pharma Company N.V. | 1/10 | 0.0% | −48.3% |
| ESTAEstablishment Labs Holdings Inc. | 1/10 | 0.0% | 5.4% |
| RGCRegencell Bioscience Holdings Limited | 1/10 | 0.0% | −56.8% |
| SLNSilence Therapeutics Plc American Depository Share | 1/10 | 0.0% | 200.2% |
| ZLABZai Lab Ltd | 1/10 | 0.0% | 22.6% |
| QUREuniQure N.V. | 1/10 | 0.0% | −18.0% |
| BHCBausch Health Companies Inc. | 1/10 | 0.0% | 26.3% |
News and filings
- Aurinia Pharmaceuticals Inc.: 10-Q — Quarterly report for the period ending 30 Sep 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 30 Oct 2026
- Aurinia Pharmaceuticals Inc.: 8-K — Results of operations
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 30 Oct 2026
- Aurinia Pharmaceuticals Inc.: 8-K — Other events
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 19 Aug 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 1 entry
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | —/10 | — · — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.